Alectinib: overview of clinical development
Study ID
Phase
Study design
Location
Data
availability
AF001JP
Phase I / II
≥2L crizotinib-naïve
(single-arm)
Japan
Published
1,2
AF002JG /
NP28761
Phase I / II
≥2L crizotinib-failure
(single-arm)
USA
Published
3,4
JO28928
(J-ALEX)
Phase III
1L / 2L crizotinib-
naïve H2H vs
crizotinib
Japan
Study
ongoing
BO28984
(ALEX)
Phase III
1L H2H vs crizotinib
Global
Study
ongoing
MO29750
Phase III
Crizotinib-failure
alectinib vs chemo
Global
Study
ongoing
1. Seto, et al. Lancet Oncol 2013; 2. Inoue, et al. WCLC 2013
3. Ou, et al. ESMO 2013; 4. Shaw, et al. WCLC 2015; 5. Ou, et al. ASCO 2015
